ML

Mineralys Therapeutics IncNASDAQ MLYS Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.72

Micro

Exchange

XNAS - Nasdaq

MLYS Stock Analysis

ML

Uncovered

Mineralys Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.72

Dividend yield

Shares outstanding

39.057 B

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

View Section: Eyestock Rating